Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zimmer and Orthofix suffer weak hip and knees; dj's regen unit carries on strongly

This article was originally published in Clinica

Executive Summary

Cost controls helped to bolster weaker-than-expected sales for Zimmer in the third quarter. While total sales reached $762.5m, a disappointing 9% increase from the same period last year, reduced general administrative and research and development expenses made up for the revenue shortfall and drove net earnings up to $168.6m or $0.70 per share, $0.03 better than analysts' consensus.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT056852

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel